Recombinant Destabilase from
Research article published in Current issues in molecular biology (2021)
Abstract
Leeches are amazing animals that can be classified as conditionally poisonous animals since the salivary cocktail they produce is injected directly into the victim, and its components have strictly defined biological purposes, such as preventing blood clot formation. Thrombolytic drugs are mainly aimed at treating newly formed blood clots. Aged clots are stabilized by a large number of isopeptide bonds that prevent the action of thrombolytics. These bonds are destroyed by destabilase, an enzyme of the leech's salivary glands. Here, we conducted a pilot study to evaluate the feasibility and effectiveness of the use of destabilase in relation to blood clots formed during real pathological processes. We evaluated the isopeptidase activity of destabilase during the formation of a stabilized fibrin clot. We showed that destabilase does not affect the internal and external coagulation cascades. We calculated the dose-response curve and tested the ability of destabilase to destroy isopeptide bonds in natural blood clots. The effect of aged and fresh clots dissolving ability after treatment with destabilase coincided with the morphological characteristics of clots during surgery. Thus, recombinant destabilase can be considered as a potential drug for the treatment of aged clots, which are difficult to treat with known thrombolytics.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Leeches are amazing animals that can be classified as conditionally poisonous animals since the salivary cocktail they produce is injected directly into the victim, and its components have strictly defined biological purposes, such as preventing blood clot formation.
Why This Matters for Hirudotherapy
This pilot study examined recombinant destabilase, an enzyme from leech salivary glands that cleaves the isopeptide bonds stabilizing aged blood clots, which resist conventional thrombolytics. The investigators evaluated its isopeptidase activity during stabilized fibrin clot formation, established that it does not affect the internal or external coagulation cascades, determined a dose-response relationship, and demonstrated its capacity to dissolve both fresh and aged natural blood clots, with observations corresponding to surgical clot morphology. This work is directly relevant to hirudotherapy and the leech salivary secretome, as it mechanistically characterizes a specific leech-derived enzyme with fibrinolytic action distinct from existing therapies. However, the abstract describes only a pilot feasibility study with limited quantitative outcome data reported, and the suggested therapeutic potential for aged clots requires substantial further validation before any clinical application could be considered.
Citation
Added to ASH library: March 18, 2026 · Site last updated: June 18, 2026